NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

TLSA

Tiziana Life Sciences Ltd

Apr 28 • 04:00PM ET

1.31

Dollar change -0.05
Percentage change -3.68	%

Healthcare • Biotechnology • United Kingdom • NASD

Peers: BMY MRK PFE GILD AMGN VRTX REGN BIIB INCY NBIX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	35.15%	Shs Outstand	102.27M	Perf Week	15.93%
Market Cap	144.96M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	71.76M	Perf Month	14.91%
Income	-	PEG	-	EPS next Q	-	Inst Own	0.91%	Short Float	1.46%	Perf Quarter	77.99%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-49.28%	Short Ratio	1.51	Perf Half Y	35.29%
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	1.05M	Perf Year	65.80%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	0.54 - 1.91	Perf YTD	88.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.98%	ROI	-	52W High	-31.41%	Beta	0.27
Dividend TTM	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	140.94%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	-	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	60.11	Volatility	14.38% 13.30%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	3.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	7.04%	Payout	-	Rel Volume	0.40	Prev Close	1.36
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	694.98K	Price	1.31
SMA20	27.02%	SMA50	14.83%	SMA200	33.56%	Trades		Volume	278,479	Change	-3.68%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-22-20	Initiated	B. Riley Securities	Buy	$8
Dec-17-18	Initiated	Laidlaw	Buy

Apr-24-25 11:14AM	Dosing begins in Tiziana Life Sciences trial of foralumab for na-SPMS (Clinical Trials Arena) +9.92%
Apr-23-25 07:00AM	Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial (GlobeNewswire) +12.93%
Apr-02-25 08:00AM	Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial (GlobeNewswire)
Mar-26-25 07:58AM	Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis (Clinical Trials Arena)
Mar-25-25 08:00AM	Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial (GlobeNewswire) +13.89%
08:00AM	Loading…
Mar-17-25 08:00AM	Tiziana Life Sciences to Present at the 37th Annual Roth Conference (GlobeNewswire)
Mar-14-25 08:30AM	Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule (GlobeNewswire) +6.08%
Mar-04-25 08:00AM	Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial (GlobeNewswire)
Mar-02-25 09:25AM	Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-27-25 08:00AM	Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury (GlobeNewswire) +15.31%
Feb-25-25 08:00AM	Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter (GlobeNewswire) +6.07%
Feb-21-25 08:00AM	Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC (GlobeNewswire) -8.90%
Feb-18-25 08:00AM	Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program (GlobeNewswire) +11.07%
Feb-11-25 09:15AM	Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease (GlobeNewswire)
Jan-23-25 03:00PM	Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3 (GlobeNewswire) +11.06%
08:54AM	Loading…
08:54AM	Tiziana Life Sciences not to engage in capital raising activities for the immediate future (GlobeNewswire)
Jan-22-25 04:05PM	Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab (GlobeNewswire) +8.51%
Jan-10-25 08:00AM	Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 (GlobeNewswire) +14.13%
Jan-08-25 07:00AM	Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease (GlobeNewswire)
Dec-17-24 07:00AM	Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab (GlobeNewswire) +6.50%
Dec-05-24 07:07AM	Tiziana Life Sciences expands Phase 2 trial for non-active SPMS (TipRanks)
Dec-04-24 07:00AM	Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers (GlobeNewswire) +12.09%
Nov-20-24 07:28AM	Tiziana Life Sciences Secures ALS Trial Funding (TipRanks)
Nov-19-24 07:00AM	Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association (GlobeNewswire)
Nov-01-24 01:00PM	Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data (GlobeNewswire)
Oct-30-24 10:29PM	Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million (GlobeNewswire) +15.69% -17.37%
08:30AM	Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study (GlobeNewswire)
Oct-26-24 05:49PM	Tiziana Life Sciences Plans Share Sale with Jefferies (TipRanks)
Oct-19-24 05:27PM	Tiziana Life Sciences Advances with Promising Drug Trials (TipRanks)
Sep-19-24 07:00AM	Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer's Disease (GlobeNewswire)
07:00AM	Loading…
Aug-19-24 07:00AM	Tiziana Life Sciences Appoints New Chief Executive Officer (GlobeNewswire) -5.79%
Aug-14-24 07:00AM	Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule (GlobeNewswire) -19.85%
Aug-10-24 02:00PM	The 3 Best EV Stocks to Buy in August 2024 (InvestorPlace)
Jul-24-24 07:00AM	Tiziana Life Sciences Granted FDA Fast Track Designation (GlobeNewswire) +11.10%
Jun-28-24 11:01AM	Tiziana Receives $3.4 Million in Non-Dilutive Funding (GlobeNewswire)
07:53AM	Tiziana Life Sciences adds to treasury with $3.4 million in non-dilutive funding (News Direct)
Jun-26-24 07:00AM	Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab (GlobeNewswire)
Jun-11-24 08:45AM	Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises (GlobeNewswire)
08:00AM	FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis (GlobeNewswire)
Jun-06-24 09:00AM	Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab (GlobeNewswire)
Jun-04-24 09:00AM	Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab (GlobeNewswire)
May-30-24 07:00AM	Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research (GlobeNewswire)
May-13-24 07:00AM	Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab (GlobeNewswire)
Apr-25-24 10:00AM	Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab (GlobeNewswire) +6.45%
Apr-23-24 09:32AM	Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program (MT Newswires)
07:00AM	Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program (GlobeNewswire)
Apr-22-24 07:00AM	Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program (GlobeNewswire) +13.15%
Apr-19-24 07:00AM	Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today (GlobeNewswire)
Apr-18-24 07:00AM	Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology (GlobeNewswire) +24.76%
Apr-11-24 07:00AM	Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology (GlobeNewswire)
Mar-05-24 07:00AM	Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease (GlobeNewswire) +9.60%
Jan-08-24 07:00AM	Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients (GlobeNewswire) -6.79%
Jan-05-24 09:30AM	Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 (GlobeNewswire)
07:00AM	Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation (GlobeNewswire)
Dec-19-23 07:00AM	Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis (GlobeNewswire) +5.45%
Dec-04-23 07:09AM	Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar (GlobeNewswire)
Nov-30-23 07:00AM	Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis (GlobeNewswire)
Nov-01-23 07:00AM	Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023 (GlobeNewswire)
Oct-20-23 05:20AM	TLSA: Six Month SPMS Results (Zacks)
Oct-18-23 07:00AM	Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment (GlobeNewswire)
Oct-17-23 03:27AM	Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial (News Direct) -14.00%
Oct-16-23 07:00AM	Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab (GlobeNewswire) +6.25%
Oct-13-23 07:00AM	Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS) (GlobeNewswire) +8.14%
Oct-11-23 07:00AM	Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress (GlobeNewswire)
Sep-26-23 07:00AM	Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis (GlobeNewswire)
Sep-12-23 08:19AM	Tiziana Life Sciences' Alzheimer's treatment validated in new study (News Direct)
Sep-08-23 07:00AM	Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-06-23 07:00AM	Study Validating MoA of Intranasal Foralumab in Alzheimers Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance (GlobeNewswire)
Aug-28-23 07:12AM	TLSA: IND Cleared by FDA and Alzheimers Deep Dive (Zacks)
Aug-23-23 10:30AM	Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer (GlobeNewswire)
07:00AM	Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology (GlobeNewswire)
Aug-17-23 07:00AM	Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease (GlobeNewswire)
Aug-15-23 09:28AM	Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment (News Direct) +36.56%
07:00AM	Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimers Disease (GlobeNewswire)
Aug-01-23 08:00AM	Proactive Analyst expects "some good news over the next 1-2 months" from Tiziana Life Sciences (News Direct)
Jul-21-23 04:15PM	Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice (GlobeNewswire)
Jun-20-23 06:07AM	TLSA: Reduced Microglial Activation in PET Scan (Zacks Small Cap Research) +6.92%
Jun-18-23 09:02AM	We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate (Simply Wall St.)
Jun-13-23 07:00AM	Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer (GlobeNewswire)
Jun-05-23 10:00AM	Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis (GlobeNewswire) -10.68%
May-25-23 07:00AM	Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) (GlobeNewswire)
May-23-23 07:00AM	Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform (GlobeNewswire)
May-17-23 07:00AM	Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17 (GlobeNewswire)
May-05-23 10:49AM	Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst (News Direct)
May-02-23 05:52AM	TLSA: SPMS Phase II to Proceed (Zacks Small Cap Research)
Apr-27-23 07:00AM	Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference (GlobeNewswire) -7.52%
Apr-26-23 02:47PM	Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update (GlobeNewswire)
Apr-24-23 07:00AM	Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule (GlobeNewswire) -5.77%
Apr-21-23 10:47AM	Tiziana Life Sciences plans to file Investigational New Drug Application for Alzheimer's treatment (News Direct) -8.72%
Apr-20-23 07:00AM	Tiziana Life Sciences to File Alzheimers IND for Intranasal Foralumab in Q2 2023 (GlobeNewswire)
Apr-19-23 10:30AM	Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis (ACCESSWIRE) -9.30%
Apr-18-23 07:00AM	Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes (GlobeNewswire) +8.40%
Apr-17-23 09:00AM	Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce Tiziana Life Sciences (NASDAQ:TLSA) First-in-Class Foralumab Is Showing Promise (ACCESSWIRE) +11.21%
05:53AM	Tiziana Life Sciences pursuing development of intranasal foralumab for Long COVID treatment (News Direct)
Apr-13-23 08:30AM	EXCLUSIVE: Tiziana Life Sciences Plans To Develop Multiple Sclerosis Hopeful For Long COVID Patients (Benzinga) +5.88%
07:00AM	Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID (GlobeNewswire)
Apr-10-23 07:00AM	Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the Preserving the Brain Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai (GlobeNewswire)
Apr-04-23 10:43AM	Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference (GlobeNewswire) -21.17%
07:00AM	Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage (GlobeNewswire)
Mar-31-23 07:00AM	Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimers Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimers and Parkinsons Disease and Related Neurological Disorders Conference in Sweden (GlobeNewswire)

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Alzheimer's. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TLSA

Tiziana Life Sciences Ltd

Upgrade your FINVIZ experience